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Since its ﬁrst description in 1910 (Wright, 1910), neuroblastoma has the Maris laboratory that demonstrated that neuroblastomas in which
emerged as one of the most common cancers in infants less than one
year of age. MYCN (MYC neuroblastoma-derived homolog) ampliﬁca-
tionwas one of the ﬁrst reliable biomarkers and is to this day an indica-
tor of rapid disease progression and poor prognosis (Huang and Weiss,
2013). High levels ofMYCN expression strongly correlate with metasta-
tic behavior, and sadly about 20% of high-risk neuroblastoma patients
are refractory to chemotherapy. MYCN is a member of the MYC family
of transcription factors all of which are homologous to the viral
oncogene v-myc (for myelocytomatosis). Similar to MYC, MYCN
heterodimerizes with MAX at E-box sequences and induces a large
number of target genes that drive proliferative responses (Huang and
Weiss, 2013). Both MYC and MYCN are difﬁcult to block directly due
to their structural speciﬁcations, and efforts aimed at functionally
inhibiting MYC family members have remained largely unsuccessful.
A study by Gu et al. in this issue of EBioMedicine demonstrates that
neuroblastomas with high-levelMYCN ampliﬁcations carry a particular
burden: they experience chronic replication stress and rely on signaling
pathways that counteract the collapse of active replication forksGu et al.
(2015). Replication stress is a collective term for challenges that can
arise during S phase and cause replication complexes to arrest. Underly-
ing causes can be the shortage of nucleotides, defects in a component of
the replicationmachinery or insufﬁcient origin activation that results in
too few replication forks to complete genome replication (Bielinsky,
2003). All of these deﬁciencies result in a delay of DNA synthesis that
leaves the unwound DNA template single-stranded. The single-
strandedDNA is rapidly bound by RPA (replication protein A),which re-
cruits the ATR (ataxia telangiectasia mutated and Rad3-related) kinase
in conjunctionwith its binding partner ATRIP (ATR interacting protein).
ATR/ATRIP then promotes the activation of CHK1, the checkpoint kinase
that shields arrested forks from collapse and concomitant inactivation
(Zeman and Cimprich, 2014).
Gu et al. had previously reported that a soluble peptide, R9-caPep,
derived from the interdomain loop of the replication clamp PCNA (pro-
liferating cell nuclear antigen) selectively inhibited the proliferation of
neuroblastoma cells that harbored MYCN ampliﬁcations (Gu et al.,
2014). However, the underlying mechanism(s) remained elusive. The
present study conﬁrms and signiﬁcantly extends previous results byDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.11.016.
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(Cole et al., 2011). Gu et al. re-analyzed microarray data from 472 neu-
roblastoma tumors and examined a total of 36 new patient-derived
specimens to validate the notion that high-level MYCN expression
strongly correlates with chronic replication stress. In a separate set of
experiments, the authors show convincingly that depletion of MYCN
in neuroblastoma cell lines reduces the basal burden of genome instabil-
ity several-fold. At the same time, chronic replication stress confers sen-
sitivity to the PCNA-derived peptide R9-caPep. The peptide interferes
with normal PCNA function likely by sequestering binding partners
whose actions PCNA coordinates during DNA replication (Stoimenov
andHelleday, 2009). Importantly, the inhibitory effect of R9-caPep is di-
minishedwhenMYCN expression is downregulated, consistentwith the
original observation that the peptide is highly effective in neuroblasto-
ma cells in which theMYCN locus is ampliﬁed.
A key experiment in this new study is a single-molecule ﬁber analy-
sis that utilizes consecutive labeling of nascent DNA by two different
thymidine analogs. When the second label was applied in the presence
of the R9-caPep peptide, replication fork progression was signiﬁcantly
reduced. It is highly unlikely that the observed effect is not speciﬁc to
the peptide sequence, as the authors had previously shown that a
scrambled control peptide did not have any inhibitory effect on DNA
synthesis nor cell growth (Gu et al., 2014). Importantly, the PCNA-
derived peptide synergizeswith CHK1 inhibitors to increase genome in-
stability, enhance the activation of so-called backup origins – another
hallmark of replication stress – and induce apoptosis in MYCN
overexpressing neuroblastoma cells. Whether the cells succumb to
RPA exhaustion (Toledo et al., 2013), which has been proposed as amo-
lecular mechanism for replication stress-induced cell death, remains to
be explored. In the same vein, it remains to be determined whether
MYCN drives cells prematurely into S phase, thereby limiting origin
licensing and restricting the number of replication forks that can active-
ly contribute to genome duplication. Alternatively, MYC has recently
been described to have an active role in replication initiation that is
completely independent of its function in transcription (Srinivasan
et al., 2013). It is conceivable that MYCN could play a similar role, lead-
ing to an overall dysregulation of origin ﬁring that causes replication
stress. Both lines of action are not mutually exclusive and could work
in concert.
Taken together, the work by Gu et al. suggests that the combination
of CHK1 inhibitors and soluble, cell penetrable PCNA-peptides thatthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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to aim at the Achilles heel ofMYCN-overexpressing neuroblastomas.Conﬂict of Interest
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